Showing 1 - 10 results of 10 for search 'massimo breccia', query time: 0.02s Refine Results
  1. 1
    SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

    SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs by Massimo Breccia, Giuliana Alimena

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia

    Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia by matteo molica, elisabetta abruzzese, massimo breccia

    Published 2020-08-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY

    MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY by Francesco Lococo, Roberto Latagliata, Massimo Breccia

    Published 2013-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

    Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia by Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

    Published 2016-02-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

    LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE by Michelina Santopietro, Giuseppina Loglisci, Roberto Latagliata, Corrado Girmenia, Massimo Breccia, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

    LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE by Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena

    Published 2011-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison

    Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison by Valentin Garcia-Gutierrez, Fei Huang, Ajibade Ashaye, Mehul Dalal, Victor Laliman-Khara, Massimo Breccia, Megan Rutherford, Hoora Moradian, Petros Patos, Elias Joseph Jabbour

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS

    EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS by Salvatore Giacomo Morano, Lorenzo Coppola, Roberto Latagliata, Paola Berneschi, Antonio Chistolini, Alessandra Micozzi, Corrado Girmenia, Massimo Breccia, Gregorio Brunetti, Angela Matturro, Giovanni Rosa, Pietro Guerrisi, Franco Mandelli, Roberto Foà, Giuliana Alimena

    Published 2014-02-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms

    Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms by Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, Aylin Yucel, Roberto Latagliata, Massimo Breccia, Giuseppe A. Palumbo, Grazia Sanpaolo, Marta Riva, Valeria Santini, Uwe Platzbecker, Guillermo Garcia-Manero, Pierre Fenaux, Christopher G. Pelligra

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY

    A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPER... by Flavia Mayer, Laura Faglioni, Nera Agabiti, Susanna Fenu, Francesco Buccisano, Roberto Latagliata, Roberto Ricci, Maria Antonietta Aloe Spiriti, Caterina Tatarelli, Massimo Breccia, Giuseppe Cimino, Luana Fianchi, Svitlana Gumenyuk, Stefano Mancini, Luca Maurillo, Carolina Nobile, Pasquale Niscola, Anna Lina Piccioni, Agostino Tafuri, Giulio Trapè, Alessandro Andriani, Paolo De Fabritis, Maria Teresa Voso, Marina Davoli, Gina Zini

    Published 2017-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: